IDH2 and acute myeloid leukemia: Acute myeloid leukemia treatments targeted at mutant IDH proteins have entered clinical routine, such as the IDH2 inhibitor enasidenib that received FDA approval for the treatment of relapsed or refractory acute myeloid leukemia on August 1, 2017 (www.fda.gov).